Brief overview of the end points of thrombolytic therapy
- 5 December 1991
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 68 (16) , 8-10
- https://doi.org/10.1016/0002-9149(91)90299-z
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials.Circulation, 1990
- Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS studyThe Lancet, 1990
- Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarctionThe Lancet, 1990
- Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarctionThe American Journal of Cardiology, 1989
- The impact of coronary thrombolysis on myocardial infarctionFibrinolysis, 1989
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarctionThe American Journal of Cardiology, 1988
- Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinaseJournal of the American College of Cardiology, 1988
- Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization studyJournal of the American College of Cardiology, 1987
- An Interim Report of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC)1Drugs, 1987